Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants
In this real-world cohort, apixaban and rivaroxaban plasma concentrations were not associated with clinical outcomes. While highlighting the limitations of analyzing clinical outcomes within the framework of a pharmacokinetic study, these data are informative for future meta-analyses aimed at minimizing publication bias from neutral results.
Authors
- Pauline Gosselin
- Youssef Daali (ORCID: https://orcid.org/0000-0002-8391-9383)
- Jean E. Terrier (ORCID: https://orcid.org/0000-0002-5878-4878)
- Pierre Fontana
- Christophe Combescure
- Jean-Luc Reny
Institutions
- University of Geneva (CH)
- University Hospital of Geneva (CH)
- Geneva College (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fphar.2026.1761151
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hôpitaux Universitaires de Genève